[1]

Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation 2019; 139: e56−e528.

[2] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373−498. doi: 10.1093/eurheartj/ehaa612 [3] Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention 2020; 15: 1133−1180. doi: 10.4244/EIJY19M08_01 [4] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534−542. doi: 10.1016/S0140-6736(09)61343-X [5] Holmes Jr DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014; 64: 1−12. doi: 10.1016/j.jacc.2014.04.029 [6]

Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol 2020; 75: 3122−3135.

[7] Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017; 70: 2964−2975. doi: 10.1016/j.jacc.2017.10.021 [8] Gloekler S, Fürholz M, de Marchi S, et al. Left atrial appendage closure versus medical therapy in patients with atrial fibrillation: the APPLY study. EuroIntervention 2020; 16: e767−e774. doi: 10.4244/EIJ-D-20-00201 [9] Nielsen-Kudsk JE, Korsholm K, Damgaard D, et al. Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation. JACC Cardiovasc Interv 2021; 14: 69−78. doi: 10.1016/j.jcin.2020.09.051 [10] Schueler R, Öztürk C, Wedekind JA, et al. Persistence of iatrogenic atrial septal defect after interventional mitral valve repair with the MitraClip system: a note of caution. JACC Cardiovasc Interv 2015; 8: 450−459. doi: 10.1016/j.jcin.2014.10.024 [11] Smith T, McGinty P, Bommer W, et al. Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system. Catheter Cardiovasc Interv 2012; 80: 678−685. doi: 10.1002/ccd.23485 [12]

Hammerstingl C, Lickfett L, Jeong KM, et al. Persistence of iatrogenic atrial septal defect after pulmonary vein isolation--an underestimated risk? Am Heart J 2006; 152: 362. e1-5.

[13] Linhart M, Werner JT, Stöckigt F, et al. High rate of persistent iatrogenic atrial septal defect after single transseptal puncture for cryoballoon pulmonary vein isolation. J Interv Card Electrophysiol 2018; 52: 141−148. doi: 10.1007/s10840-018-0352-0 [14] Singh SM, Douglas PS, Reddy VY. The incidence and long-term clinical outcome of iatrogenic atrial septal defects secondary to transseptal catheterization with a 12F transseptal sheath. Circ Arrhythm Electrophysiol 2011; 4: 166−171. doi: 10.1161/CIRCEP.110.959015 [15] Puga L, Teixeira R, Paiva L, et al. Iatrogenic atrial septal defect after percutaneous left atrial appendage closure: a single-center study. Int J Cardiovasc Imaging 2021; 37: 2359−2368. doi: 10.1007/s10554-021-02212-4 [16]

Omran H, Hardung D, Schmidt H, et al. Mechanical occlusion of the left atrial appendage. J Cardiovasc Electrophysiol 2003; 14(9 Suppl): S56-S59.

[17] Nelles D, Vij V, Al-Kassou B, et al. Incidence, persistence, and clinical relevance of iatrogenic atrial septal defects after percutaneous left atrial appendage occlusion. Echocardiography 2022; 39: 65−73. doi: 10.1111/echo.15271 [18] Alachkar MN, Alnaimi A, Reith S, et al. Incidence and clinical relevance of persistent iatrogenic atrial septal defect after percutaneous mitral valve repair. Sci Rep 2021; 11: 12700. doi: 10.1038/s41598-021-92255-3 [19] Paukovitsch M, Schneider LM, Reichart C, et al. Prevalence of iatrogenic atrial septal defects (iASD) after mitral valve (MV) transcatheter edge-to-edge repair (TEER) in the long-term follow-up. Open Heart 2021; 8: e001732. doi: 10.1136/openhrt-2021-001732 [20]

Maier O, Hellhammer K, Horn P, et al. Iatrogenic atrial septal defect persistence after percutaneous mitral valve repair: a meta-analysis. Acta Cardiol 2021: 1-11.

[21] Lurz P, Unterhuber M, Rommel KP, et al. Iatrogenic Atrial Septal Defects Following Transcatheter Mitral Valve Repair and Implications of Interventional Closure. JACC Cardiovasc Interv 2021; 14: 2685−2694. doi: 10.1016/j.jcin.2021.09.023 [22] Ikenaga H, Hayashi A, Nagaura T, et al. Left atrial pressure is associated with iatrogenic atrial septal defect after mitral valve clip. Heart 2019; 105: 864−872. doi: 10.1136/heartjnl-2018-313839 [23] Sieira J, Chierchia GB, Di Giovanni G, et al. One year incidence of iatrogenic atrial septal defect after cryoballoon ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2014; 25: 11−15. doi: 10.1111/jce.12279 [24]

Eden M, Leeb L, Frey N, Rosenberg M. Haemodynamics of an iatrogenic atrial septal defect after MitraClip implantation. Eur J Clin Invest 2020; 50: e13295.